日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

SHR-A1811, a novel HER2-targeting antibody-drug conjugate, in advanced solid tumors (HORIZON-X): a global phase 1 trial

SHR-A1811,一种新型靶向 HER2 的抗体药物偶联物,在晚期实体瘤中的应用(HORIZON-X):一项全球 1 期试验

Yao, Herui; Yan, Min; Tong, Zhongsheng; Wu, Xinhong; Yin, Yongmei; Ryu, Min-Hee; Park, John J; Jiang, Shusuan; Kim, Jee Hyun; Wang, Shouman; Zhong, Yahua; Voskoboynik, Mark; Zhang, Jian; Kaubisch, Andreas; Liu, Caigang; Chen, Yu; Im, Seock-Ah; Wu, Lingying; Liu, Yingbin; Ganju, Vinod; Barve, Minal; Li, Hui; Yao, Guangyu; Yang, Mudan; Bao, Lequn; Zhao, Yiming; Zhao, Jianli; Zhao, Kaijing; Shen, Yu; Rong, Shangyi; Zhu, Xiaoyu; Song, Erwei

Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects

克隆性造血与曲妥珠单抗相关心脏毒性风险

Park, Chan Soon; Ryu, Gangpyo; Ahn, Hyo-Jeong; Sun, Choonghyun; Lee, Seung-Pyo; Kim, Hyung-Kwan; Kim, Yong-Jin; Jeon, Sook Young; Lee, Han-Byoel; Moon, Hyeong-Gon; Han, Wonshik; Lee, Dae-Won; Lee, Kyung-Hun; Han, Sae-Won; Im, Seock-Ah; Lee, Sang Eun; Jaiswal, Siddhartha; Koh, Youngil; Park, Jun-Bean

Cancer Manipulates Adjacent Adipose Tissue to Exploit Fatty Acids via HIF-1α/CCL2/PPARα Axis: A Metabolic Circuit to Support Tumor Progression.

癌细胞通过 HIF-1α/CCL2/PPARα 轴操纵邻近脂肪组织以利用脂肪酸:一种支持肿瘤进展的代谢回路。

Yun Jeong-Eun, Seo Jieun, Koh Jiwon, Im Seock-Ah, Hong Ki Yong, Son Yeseon, Jeong Do-Won, Fukuda Junji, Park Jong-Wan, Chun Yang-Sook

DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer

DESTINY-Breast08:曲妥珠单抗德鲁替康联合其他抗癌疗法治疗HER2低表达转移性乳腺癌患者的Ib期研究

Jhaveri, Komal; Loi, Sherene; Hamilton, Erika; Schmid, Peter; Anders, Carey K; Testa, Laura; Wildiers, Hans; Tseng, Ling-Ming; Lu, Yen-Shen; Park, Yeon Hee; Im, Seock-Ah; Chen, Shin-Cheh; Young, Robyn R; Lloyd, Caron; Wrona, Magdalena; Zhang, Cuihong; Carroll, Danielle; André, Fabrice

Redefining HER2 in Breast Cancer: From Conventional Positivity to Low and Ultralow in the New Era of Antibody-Drug Conjugates

重新定义乳腺癌中的HER2:从传统阳性到抗体药物偶联物新时代的低表达和超低表达

Koh, Jiwon; Im, Seock-Ah

DNA Damage and Nuclear Anaplasia Induced by Trastuzumab Deruxtecan in Cancer Cells with Variable HER2 Expression and Homologous Recombination Deficiency Status.

曲妥珠单抗德鲁替康在HER2表达和同源重组缺陷状态不同的癌细胞中诱导DNA损伤和核异型性。

Kim So Hyeon, Park Yoonjung, Min Ahrum, Park Hye Yeon, Kim Yu-Jin, Ham Sujin, Koh Jiwon, Kim Seongyeong, Lee Dae-Won, Ryu Han Suk, Kim Jin-Soo, Lee Kyung-Hun, Im Seock-Ah

Elimusertib, a Novel ATR Inhibitor, Induces Anti-tumor Effects through Replication Catastrophe in Breast Cancers.

Elimusertib 是一种新型 ATR 抑制剂,可通过乳腺癌中的复制灾难诱导抗肿瘤作用。

Kim Mudong, Min Ahrum, Kim Sohyeon, Kim Seongyeong, Kim Yu-Jin, Ham Sujin, Lee Miso, Lee Eunice Yoojin, Kim Jinyong, Lee Dae-Won, Lee Kyung-Hun, Im Seock-Ah

Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial

辅助性阿特珠单抗治疗早期三阴性乳腺癌:ALEXANDRA/IMpassion030随机临床试验

Ignatiadis, Michail; Bailey, Andrew; McArthur, Heather; El-Abed, Sarra; de Azambuja, Evandro; Metzger, Otto; Chui, Stephen Y; Dieterich, Max; Perretti, Thomas; Shearer-Kang, Esther; Molinero, Luciana; Steger, Günther G; Jassem, Jacek; Lee, Soo Chin; Higgins, Michaela; Zarba, Jose; Schmidt, Marcus; Gomez, Henry; Guerrero Zotano, Angel; Moscetti, Luca; Chiu, Joanne; Munzone, Elisabetta; Ben-Baruch, Noa Efrat; Bajetta, Emilio; Ohno, Shinji; Im, Seock-Ah; Werutsky, Gustavo; Gal-Yam, Einav Nili; Gonzalez Farre, Xavier; Tseng, Ling-Ming; Jacot, William; Gluz, Oleg; Shao, Zhimin; Shparyk, Yaroslav; Zimina, Anastasia; Winer, Eric; Cameron, David A; Viale, Giuseppe; Saji, Shigehira; Gelber, Richard; Piccart, Martine

Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial

曲妥珠单抗德鲁替康治疗HER2低表达转移性乳腺癌:随机3期DESTINY-Breast04试验的长期生存分析

Modi, Shanu; Jacot, William; Iwata, Hiroji; Park, Yeon Hee; Vidal Losada, Maria; Li, Wei; Tsurutani, Junji; Ueno, Naoto T; Zaman, Khalil; Prat, Aleix; Papazisis, Konstantinos; Rugo, Hope S; Yamashita, Toshinari; Harbeck, Nadia; Im, Seock-Ah; De Laurentiis, Michelino; Pierga, Jean-Yves; Wang, Xiaojia; Gombos, Andrea; Tokunaga, Eriko; Orbegoso Aguilar, Cecilia; Yung, Lotus; Xiao, Feng; Cheng, Yingkai; Cameron, David

Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)/HER2(-) breast cancer: a randomized phase 3 trial

帕博利珠单抗联合化疗治疗高危早期ER(+)/HER2(-)乳腺癌:一项随机3期试验

Cardoso, Fatima; O'Shaughnessy, Joyce; Liu, Zhenzhen; McArthur, Heather; Schmid, Peter; Cortes, Javier; Harbeck, Nadia; Telli, Melinda L; Cescon, David W; Fasching, Peter A; Shao, Zhimin; Loirat, Delphine; Park, Yeon Hee; Fernandez, Manuel Gonzalez; Rubovszky, Gábor; Spring, Laura; Im, Seock-Ah; Hui, Rina; Takano, Toshimi; André, Fabrice; Yasojima, Hiroyuki; Ding, Yu; Jia, Liyi; Karantza, Vassiliki; Tryfonidis, Konstantinos; Bardia, Aditya